Abstract. Lack of the normal p53 transactivation domain, ∆133p53 isoform exhibits anti-p53 function. Many studies report the correlation between ∆133p53 expression and poor survival in various cancers, including cholangiocarcinoma (CCA), which is a cancer of the bile ducts. CCA almost always results in short survival times. The relevance of ∆133p53 to drug resistance in CCA is not yet well understood. This study aimed to demonstrate the association between ∆133p53 and 5-fluorouracil (5-FU) resistance in CCA. ∆133p53 protein was highly expressed in CCA patients with poor outcome compared to favorable outcome but was not statistically significant. However, a significant correlation was found between normalized ∆133p53 levels and 5-FU resistance which was defined by an ex vivo histoculture drug response assay (P=0.019). Two stable 5-FU-resistant CCA cell lines, KKU-M139R (IC 50 38.8 µM) and KKU-M214R (IC 50 39.5 µM), were used as a model to evaluate the role of ∆133p53. Increased ∆133p53 was correlated with 5-FU in a dose-dependent manner. The transient knockdown of ∆133p53 expression can restore drug sensitivity in both resistant CCA cells with 11-to 45-fold reduction of IC 50 compared to control. Upon ∆133p53 silencing, apoptotic signaling was enhanced by the upregulation of Bax and downregulation of Bcl-2. Additionally, p21 and p27 were upregulated, resulting in cell cycle arrest at G2. Inhibition of colony formation and prolong doubling time were also observed. Our findings demonstrated that chemosensitivity can be modulated via targeting of ∆133p53 suggesting the potential use of ∆133p53 as a candidate for targeting therapy in CCA.
Introduction
Cholangiocarcinoma (CCA) is a cancer arising from bile duct epithelium. The highest prevalence of CCA in the world has been reported in the northeastern regions of Thailand, where liver fluke infection is highly endemic (1) (2) (3) . The etiology of the disease is related to chronic biliary inflammation caused by the consumption of raw or undercooked fish that is infected with the liver fluke Opisthorchis viverrini, together with foods containing N-nitroso compounds (4, 5) . Only CCA patients with early stage disease are curable by surgical treatment (6) . However, the early stage disease is asymptomatic and difficult to diagnose. Treatment for advance stage CCA is rather unsuccessful. Most CCA patients have different chemotherapeutic responses even at the same stage, leading to poor clinical outcomes with short survival times of ~5-7 months (7). 5-Fluorouracil (5-FU) is recommended in low resource countries as the first line drug of choice for the treatment of a variety of solid tumors including CCA (8) . However, 5-FU is rather ineffective treatment for CCA, with a response rate <10% (9) . Several reports have noted the effectiveness of other anticancer drugs in CCA such as cisplatin (10, 11) , doxorubicin (10) and gemcitabine (12) . Unfortunately, the survival time was not significantly improved which was ~6-9 months (9) . Therefore, the use of drug combinations rather than single drug has been proposed for obtaining better response in CCA. A response rate of ≤40% was obtained with the triple combination of cisplatin, epirubicin and 5-FU (13) . However, using more anticancer drugs may produce additional adverse effects and acquired drug resistance in patients.
5-FU is an inhibitor of thymidylate synthase leading to inhibition of RNA and DNA synthesis of tumor cells. DNA damage can trigger the induction of p53-dependent cell cycle arrest and apoptosis, resulting in tumor cell death (14, 15) . Although downregulation of p53 mRNA, a p73 family member, has been reported in 5-FU-resistant CCA cell lines by Namwat et al (16) no information regarding p53 role in 5-FU-resistant CCA cells has been reported. The p53 gene contains two alternative promoters (P1 and P2). The P1 promoter generates the full-length TAp53 and ∆40p53, a 40 amino acids deleted p53 variant via alternative splicing and initiation of translation (17) . The assembly of full-length p53 molecules as a tetramer leads to normal function as a transcription factor. The P2 promoter encodes larger amino-terminal truncated proteins (133 and 160 deleted amino acids), ∆133p53 (17) and ∆160p53 (18) , which exhibit anti-apoptotic properties when oligomerized with TAp53 resulting in loss of the transactivation function. The N-terminal deleted p53 protein variant (∆Np53) has been reported to disrupt wild-type p53 function (19) . Hence, the control of promoter usage in p53 is proposed as an auto-regulation mechanism for p53 functions (20) . In addition to the ∆Np53 isoforms, three alternate isoforms of p53; α, β and γ at the carboxyl terminal are encoded by alternative splicing. A full-length p53 or TAp53α is encoded from the normal splice site, whereas TAp53β and TAp53γ are encoded from two different alternative splicing sites of intron 9 at carboxyl end (17) . To date, any impact of β and γ isoforms on tumor suppressor activities remains unclear. An increase in ∆133p53 expression has also been reported in renal cell (21) , acute myeloid leukemia (22) , ovarian cancer (23), breast (17) , head and neck (24) , melanoma (25) , colon cancer (19) . The correlation between ∆133p53 and tumor progression has been found in colon carcinomas (19) . Our previous study also found the relationship between overexpression of defective p53 (mutant p53 and ∆133p53) with poor prognosis in CCA (26). Upregulation of ∆133p53 mRNA level and ratio disruption of the p53 isoforms encoded from P2/P1 (∆133p53/TAp53) was correlated with poor survival outcome of CCA patients. The major factors affecting the patients survival outcome may be the contribution from drug resistance. Reports of ∆133p53 effects on drug resistance are few. Recently, upregulation of ∆133p53α in response to a low dose of doxorubicin has been noted in osteosarcoma and colon cancer cell lines (27) . However, the role of ∆133p53 isoforms in drug resistance in CCA remains unclear.
This study attempts to demonstrate the association between ∆133p53 overexpression and chemoresistance in CCA. 5-FU sensitivity in clinical tissues of CCA was classified using an ex vivo histoculture drug response assay (HDRA) and clinical treatment outcome. Two 5-FU-resistant CCA cell lines were established in this study and used as a model to evaluate the role of ∆133p53 isoform in chemosensitivity.
Materials and methods
Clinical samples. A total of 22 tumor samples and 10 normal adjacent tissues were collected from intrahepatic cholangiocarcinoma (ICC) patients who were admitted to Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Thailand. The project was approved by the Khon Kaen University Ethics Committee in human research (HE571044). All patients gave written informed consent. Fresh tumor tissues were tested for Histoculture Drug Response Assay. Paralleled tissues were kept under liquid nitrogen until used for protein extraction.
Histoculture drug response assay (HDRA). Tumor tissues were classified as 5-FU sensitive and 5-FU resistant based on results obtained from an ex vivo histoculture drug response assay (HDRA), using the median of inhibition index (% II) as previously described (28) . In brief, fresh tumor tissues were washed and a 3-mm diameter punch was used aseptically to take samples that were placed on collagen gel sponges. Each was cultured at 37˚C in a 6-well plate containing RPMI medium supplemented with 2.5% v/v penicillin-streptomycin-fungizone (PSF; Invitrogen, Carlsbad, CA, USA) and 5-FU at 200 µM. For a control sample, no 5-FU was added in the culture medium. After 4 days of culture, the viability of tumor cells in the cultured tissues was examined using TUNEL staining. TUNEL-positive cells were identified as dead cells. The efficacy of 5-FU was calculated and expressed as the % II using the following formula: % II = (1 -% viable tumor cells in 5-FU-treated tumor tissue / % living tumor cells in control tissue) x 100.
CCA cell lines and cell culture. Two CCA cell lines, KKU-M139 and KKU-M214 were established from primary tumors of human intrahepatic CCA at the Liver Fluke and Cholangiocarcinoma Research Center, Khon Kaen University Thailand (16, 29, 30) . Both were cultured at 37˚C in RPMI medium (Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), 1% v/v penicillin-streptomycin solution (Gibco, BRL) under 5% CO 2 atmosphere. These CCA cells were named as KKU-M139P and KKU-M214P, to identify the parental cell lines at the beginning of drug resistance induction.
Establishment of 5-FU-resistant CCA cell lines. 5-FU-resistant cell lines were generated from the parental cell lines KKU-M139P and KKU-M214P by stepwise increases of the concentration of 5-FU (Boryung Pharm, Korea) as described previously (16) . In brief, 1x10 5 cells were seeded in 25-cm 2 flasks and cultured without 5-FU for 24 h. Subsequently, cells were exposed with 5-FU at 6 µM for KKU-M139 (1X IC 50 value of KKU-M139P) and 4 µM for KKU-M214 (1X IC 50 value of KKU-M214P) for 72 h. Cells were then cultured in a drug-free medium until they reached 70% confluence. These cells were continuously maintained in 1X IC 50 for several passages until these cells were stable before being subjected into 2X IC 50 . The 5-FU-resistant clones were finally obtained after continuous selection by several passages for 18 months. The IC 50 of the resistant clones was checked by the SRB assay (31). The resistant clones were then passaged into a drug-free medium for 2 weeks before being stored as a stock of the resistant cell lines (KKU-M139R and KKU-M214R) at -80˚C. KKU-M139R and KKU-M214R were cultured in 5-FU-free medium for ≥2 weeks to eliminate potential long-term effects of 5-FU unrelated to drug resistance prior to being performed in all experiments.
Transient silencing of ∆133p53 by siRNA. Expression of ∆133p53 in KKU-M139R and KKU-M214R cells was suppressed using a siRNA technique. The sequences of two specific siRNA targeting human ∆133p53 (∆133p53a and ∆133p53b) as described previously (18), were purchased from Ambion (Austin, TX, USA). The cells (2x10 6 cells/well) were seeded in a 6-well plate and cultured overnight before being transfected separately with 100 pM of si∆133p53a and si∆133p53b, while siGFP (Green fluorescence protein, Applied Biosystems/Ambion, Carlsbad, CA, USA) was used as a siRNA control. Transfection was carried out using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. After 24 h of transfection, culture medium was added and the plates were incubated at 37˚C for a further 48 h. At 72 h-post transfection, total proteins were extracted using TRIzol reagent (Invitrogen). The level of ∆133p53 protein was determined by western blot analysis using β-actin as a loading control. 50 by Sulforhodamine B (SRB) assays. The parental CCA cells (KKU-M139P and KKU-M214P) and the 5-FU-resistant cells (KKU-M139R and KKU-M214R) were seeded at 1x10 4 cells/well in triplicate into a 96-well culture plate and incubated at 37˚C for 24 h. All cell lines were then treated with various concentrations of 5-FU ranging from 2-128 µM in triplicate for 72 h, while 0.9% saline was used as a negative control. The cytotoxicity was performed using a sulforhodamine B (SRB) assay as previously described (31) . The cells were fixed using a 10% cold trichloroacetic acid (TCA), washed and air-dried at room temperature. SRB (Sigma-Aldrich, MO, USA) solution (100 µl/well) was added and followed by three quick rinses with 1% acetic acid to remove unbound dye. SRB was solubilized in a 10 mM Tris base solution and the absorbance at 490 nm was measured using a microplate reader (Tecan Ltd., Reading, UK). Percentage of cell viability was calculated [(mean OD sample -mean OD day0 / mean OD negative control -mean OD day0 ) x 100] and used to generate the curve by which IC 50 was calculated. Resistance index was defined as a ratio of the IC 50 value of drug resistant cells to parental cells.
Measurement of IC

Population doubling time (PDT).
To assess cell growth, the population doubling time (PDT) of the cells was assessed in triplicate. Cells (2x10 5 ) were cultured in a drug free medium supplemented with 10% FBS at 37˚C in a humidified 5% CO 2 atmosphere. When reaching 70% confluence, the cells were trypsinized, stained with trypan blue and counted on a hemocytometer. PDT was calculated using the following formula as described previously (32): (T-T 0 ) log2/logN-logN 0 , where N 0 is the initial cell number, N is the final cell number, T is the time interval between N 0 and N, and T 0 is the initial time.
Colony forming assay. KKU-M139R and KKU-M214R cells were pre-treated with either si∆133p53 or siRNA control. The cells were seeded at 200 cells/well in a 6-well plate containing 2 ml RPMI culture medium supplemented with 10% v/v FBS and cultured at 37˚C in a humidified 5% CO 2 atmosphere for 5 days. The cells were washed twice with PBS, stained with H&E and the colonies were counted. Cell cycle analysis by flow cytometry. KKU-M139R and KKU-M214R cells (10 5 cells/ml) were incubated with or without si∆133p53 or a siRNA control for 48 h. The cells were collected, washed with cold PBS, fixed in cold 100% ethanol, treated with DNase-free RNase, and stained with 40 µg/ml of propidium iodide (PI). The distribution of the cells between phases of the cell cycle was deduced from the DNA content on a FACScan flow cytometer (BD FACSCanto II; BD, USA). For each sample, 10,000 gated events were acquired.
Analysis of apoptosis by
Western blot analyses. Protein was extracted from CCA tissues and cell lines using TRIzol (Invitrogen) and 40 µg aliquots were fractionated on 15% polyacrylamide gel electrophoresis. Primary antibodies; CM-1 (1:100, Signet, Emeryville, CA, USA), p21 (1:400), p27 (1:400), Bcl-2 (1:200), Bax (1:200), and p73 (ab-4) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) as well as a loading control, β-actin (1:4,000, Sigma Chemical Co.) were used followed by the secondary antibody peroxidaselabeled anti-rabbit (1:10,000, Abcam, UK) The proteins were detected by chemiluminescence using the ECL Plus system (GE Healthcare, UK). Protein band intensity was calculated by Scion image program, and normalized to β-actin.
Immunocytochemical staining of p53. The paraffin-embedded sections (5 µm) of CCA cell pellets fixed with 10% formalin solution were deparaffinized. Antigen retrieval was performed in boiling 0.01 M citrate buffer (pH 6.0) as described previously (26) . Endogenous peroxidase was inactivated with 100 µl of 3% H 2 O 2 . Non-specific binding was further treated with a blocking buffer containing phosphate-buffered saline with Tween-20 (PBS-T), 30% casein and 5% FBS. For p53 protein detection, mutant p53 was detected with the primary antibody clone DO-7, 1:100 (Dako, Glostrup, Denmark), which recognizes an epitope between amino acids 1-45 of human p53. The slides were incubated overnight at room temperature with primary antibody. Proteins were detected using the Envision system (Dako) for 1 h at room temperature. Color was developed with DAB solution (Dako) and nuclei were counterstained with hematoxylin. Positive staining was observed as brown color in blue/gray nuclei. Positive with DO-7 antibody indicates overexpression of the mutated p53 due to its stability (26, (33) (34) (35) .
Statistical analyses. Statistical analyses were performed using SPSS for windows version 15 (SPSS, Inc., IL, USA). The Mann-whitney U test was used for comparison of two groups. Data are expressed as mean ± SD from three independent experiments. Statistically significant differences are indicated in the figures as 
Results
Assessment of 5-FU sensitivity in CCA samples. 5-FU sensitivity in 22 CCA patients was classified based on the results obtained from histoculture drug response assays (HDRA) and treatment outcome data. For the HDRA-based classification, we used the median of the % inhibition index (% II) which was 36.5% and this identified 11 patients as 5-FU-sensitive and 11 as 5-FU-resistant. Only 12 of 22 CCA patients underwent complete course of chemotherapy. The treatment outcome was further followed up every 6 months for ≥12 months. Poor response (n=7) and favorable response (n=5) were defined in terms of having tumor progression before and after 6 months after treatment, respectively. All clinical data are summarized in Table I .
Levels of the ∆Np53 isoform are increased significantly in 5-FU-resistant CCA samples. western blot analysis of 22 tumors and 10 normal paired tissues using CM-1 antibody revealed the presence of various p53 isoforms (Fig. 1) . At least 3 isoforms; TAp53, ∆40p53 and ∆133p53 were observed in tumor tissues, in which two different sizes of ∆133p53 at 35 kDa corresponding to ∆133p53α and 28 kDa to ∆133p53β, γ were defined (Fig. 1A) . Interestingly, no ∆133p53 isoform was observed in the normal tissues (Fig. 1A) . The box-plot analysis of ∆133p53 protein expression normalized to β-actin and 5-FU sensitivity classified by HDRA showed significantly increased ∆133p53 in 5-FU-resistant cases compared to sensitive ones (P=0.019) (Fig. 1B) . It seemed that ∆133p53 protein was highly expressed in CCA patients with poor outcome compared to CCA cases with favorable outcome but was not statistically significant (P=0.264) (Fig. 1C) . Table I . Clinicopathological data of 22 CCA patients. Table II .
Chemosensitivity b --------------------------------------------------------------------
Upregulation of the ∆133p53 isoform induced by 5-FU.
The expression of p53 isoforms was assessed in both parental and resistant CCA cell lines in response to 5-FU concentration covering their IC 50 values. when challenged with 5-FU with 5 and 10 µM, TAp53, ∆40p53 and ∆133p53 protein isoforms were markedly increased in both parental cell lines (KKU-M139P and KKU-M214P) in a dose-dependent manner (Fig. 3) . This finding indicates the increased usage of both P1 and P2 promoters under 5-FU stress. In contrast to parental cells, only ∆133p53 protein was upregulated in both resistant cell lines (KKU-M139R and KKU-M214R) induced by 5-FU (Fig. 3) suggesting the enhancement of P2 promoter usage. expression of ∆133p53 was successfully suppressed with both si∆133p53a and si∆133p53b compared to the siRNA control ( Fig. 4A and B ) with normal apparent morphology (Fig. 4C) . The effect of silenced ∆133p53 on apoptotic and cell cycle markers in KKU-M139R and KKU-M214R was investigated. The suppression of ∆133p53 protein resulted in significant upregulation of Bax expression in both KKU-M214R and KKU-M139R (P<0.01) as well as downregulation of Bcl-2 in KKU-M214R (P<0.001) and KKU-M139R (P<0.01) (Fig. 4D) . Accordingly, Annexin v/PI staining showed significantly increased cell apoptosis in the silenced si∆133p53 of both KKU-M139R and KKU-M214R (si∆133p53a at P<0.01 and si∆133p53b at P<0.001, respectively) compared with control (Fig. 5) . Additionally p21 and p27 proteins were significantly upregulated with P<0.01 and P<0.001 in M139R and KKU-M214R compared to the siRNA control (Fig. 4A and 4D) . Moreover, cells were significantly arrested at G2 in both si∆133p53a and si∆133p53b treated KKU-M139R and KKU-M214R compared to the siRNA controls (Fig. 6) . Interestingly, significant upregulation of p73 was observed in both types of silenced CCA cells ( Fig. 4A and D) . Moreover, no mutated p53 was revealed in si∆133p53 treated (KKU-M139R and KKU-M214R) or siRNA control compared to their parental cells (KKU-M139P and KKU-M214P) using immunostaining with DO-7 (Fig. 7) . These results imply that the induced p73 protein might help mediating apoptosis upon the absence of wild-type TAp53 (Fig. 3A) and mutated p53 (Fig. 7) . Moreover, the induced cell cycle arrest by ∆133p53 silencing leads to growth retardation, as shown by the prolonged PDT (Fig. 8A ) and the inhibition of colony forming capability (Fig. 8B) . Hence, suppression of ∆133p53 expression affects certain tumor characteristics of these CCA resistant cells.
Attenuation of ∆133p53 levels enhances the chemosensitivity of 5-FU-resistant CCA cells.
The chemosensitivity of KKU-M139R and KKU-M214R cells transfected with si∆133p53a and si∆133p53b was re-assessed using an SRB assay of cell numbers (Table III) . Strikingly, the IC 50 of KKU-M139R-si∆133p53a and KKU-M139R-∆133p53b cells 
Discussion
A variety of ∆Np53 isoforms generated from both P1 and P2 promoters were reported in clinical tumors, however, limited evidence of chemoresistance has been noted. This study is the first to demonstrate the correlation between high levels of ∆133p53 expression in clinical CCA tissues with 5-FU resistant based HDRA. A limited sample sizing, resulting from an incomplete treatment, affected the statistical testing for correlation in clinical treatment. Even though ∆133p53 expression showed no significant correlation with clinical treatment outcome, ∆133p53 level seemed to increase in patients with poor response to treatment. This result suggested that ∆133p53 might be involved on drug responsiveness. Aoubala et al reported the upregulation of ∆133p53α with response to a low dose of doxorubicin in osteosarcoma and colon cancer (27) . However, p53 function can be inactivated by either mutation or ∆133p53 overexpression, thus, the mutant p53 should also be considered in clinical CCA. The incidence of p53 mutation has been reported in clinical CCA samples as up to 41-44% (26,36) . Defective p53 due to mutation has been reported with drug resistance to 5-FU-based therapy in colorectal cancer (37) (38) (39) . A correlation between p53 mutation and platinumbased chemotherapy resistance, early relapse, and shortened overall survival was reported in ovarian cancer patients (40) . Of note, the incidence of ∆ Np53 overexpression without mutant p53 in CCA has been previously found at 54% (26) . Therefore, the 5-FU-resistant CCA cell lines KKU-M139R and KKU-M214R were used as an in vitro model to address the impact of ∆133p53 on 5-FU resistance without the influence of p53 mutation. These 5-FU-resistant CCA cell lines contain only ∆133p53 protein without the full length p53 (TAp53) or the mutated p53 as shown by negative western blotting with CM-1 and negative DO-7 staining. The IC 50 of 5-FU resistance remained stable even cultured in drug free medium for ≥4 weeks, supporting the claim for stable resistant clone.
For both parental CCA cell lines, 5-FU can enhance the upregulation of both TAp53 and ∆133p53 in a dose-dependent manner. The enhancement of both P1 and P2 promoter usage might provide an advantage of apoptosis evasion via p53 inactivation which enabling an acquired 5-FU resistance upon drug exposure. Similar finding of ∆133p53 upregulation in response to 5-FU was revealed in both resistant cells except TAp53 existence. The enhancement of P2 promoter regardless of TAp53 may result from continuous selective pressure upon induction of 5-FU resistance. The rapid response to lower dose of 5-FU found in KKU-M214R, may explain the higher resistance index of KKU-M214R (10.12-fold) than that of KKU-M139R (6.26-fold). Targeting of ∆133p53 in 5-FU resistant cells by siRNA is therefore verified the role of ∆133p53 on chemoresistance in these 5-FU-resistant CCA cell lines which was successfully obtained by both si∆133p53a and si∆133p53b with 75-90% suppression. Interestingly, the targeting of ∆133p53 helps restoring the 5-FU sensitivity with markedly reduced IC 50 compared to that of parental cells. The molecular underlying mechanism of 5-FU resensitization can be explained by an increase of cell apoptosis via an upregulation of pro-apoptotic BAX and downregulation of anti-apoptotic Bcl-2. Moreover, G2 arrest was induced by upregulation of p21 and p27 in comparison with siRNA control cells. This evidence is relevant to the antitumor activity of 5-FU which is known to be involved in the induction of p53-dependent cell cycle arrest and apoptosis (37, 39, 41) .
Regardless of TAp53, the suppressed ∆133p53 can explain only the withdrawal of p53 inactivation, but is unable to provide clues for p53 activation. The increase of p73 expression observed by western blotting in both types of silenced ∆133p53 CCA cells might be responsible for p53 function restoration. p73, as a p53 family member, has been shown to possess the capability to restore p53 function via p21 activation in a neuroblastoma cell line (42) . The p73 protein can activate upstream transcriptional regulation of p21 and p27, resulting in cell cycle arrest in G2 (43) (44) (45) . In human lung adenocarcinoma, p73 overexpression can enhance chemosensitivity by apoptosis induction (46, 47) . Namwat et al (16) , reported the association between downregulation of TAp73 mRNA and 5-FU-resistant CCA cell lines. Evasion of apoptosis and cell cycle arrest are evident as a common mechanism of 5-FU resistance in various cancers such as colorectal cancer (48) , breast cancer (49) , and CCA (16, 29) . Recently, evasion of both intrinsic and extrinsic apoptotic pathway has been reported in gemcitabine-resistant CCA cell lines (32). Thus, ∆133p53 may exert a signature of chemoresistant cells to evade p53-dependent cell apoptosis and cell cycle arrest.
Collectively, the silencing of ∆133p53 and increased p73 expression may modulate the chemosensitivity of 5-FU resistance in CCA cell lines. Low incidence of p73 mutation has been reported in CCA (50) , downregulation via p73 methylation has been frequently found in various cancers (51) (52) (53) (54) including CCA (55) . Data on the alteration of p73 for chemoresistance in CCA is still limited. The status of p73 should be investigated in further study.
In conclusion, this study is the first to demonstrate the important role of ∆133p53 in 5-FU resistance in CCA. The attenuation of p53 by molecular targeting of ∆133p53 may modulate the chemosensitivity in CCA, hence the potential for use of ∆133p53 as a candidate for targeted therapy. 
